



10745 Westside Way, Suite 200,
Alpharetta, GA 30009
Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. Appendix 4C and Cash Flow Report

Atlanta, Georgia, USA 18 October 2017: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) Contact Lenses has today released its Appendix 4C - Quarterly Cash Flow for the period ended 30 September 2017 (third quarter FY17).

The Company has reported sales revenue of US\$354,325, a 90% increase over the previous quarter (US\$186,156). The increase in revenue is mostly attributable to quarter over quarter growth in active accounts (eye care professional offices that purchased during the quarter). Active accounts increased by 233 from 2Q2017's 295 active accounts, to 528 at the end of 3Q2017; a 79% increase.

Net operating cash outflow for the quarter was US\$3,470,000, which is comparable to the previous period ended 30 June 2017's net operating cash outflow at US\$3,449,000. Cash receipts from customers for the quarter were US\$177,000 and end of quarter cash on hand was US\$19,832,000.

	Q3 FY16 (US\$)	Q2 FY17 (US\$)	Q3 FY17 (US\$)	Quarter on Quarter % Change	Year on Year % Change
Sales Revenue	\$68,620	\$186,156	\$354,325	90%	416%
Active Accounts	95	295	528	79%	456%

Cash outflows in 4Q2017 are expected to increase to approximately US\$4.3 million from approximately \$3.5 million in 3Q2017, mostly due to additional headcount and other cash outflows to fund our on-going market expansion.

In August 2017, the Company added 8 sales personnel, bringing total sales personnel to 23 at the end of 3Q2017. Those personnel have already been trained and are adding new accounts.

"We are pleased with the continued acceleration in sales and active account creation achieved in the third quarter" said Dr Stephen Snowdy, CEO and Executive Director of Visioneering. "The results reflect the market's increasing recognition of the strong clinical benefits of our contact lens products."

Investor Conference Call

Investors are invited to join a conference call on Thursday 19th October 2017 at 9.00am AEDT (Wednesday 18th October 6.00pm EDT) hosted by Visioneering Technologies CEO Stephen Snowdy.

To pre-register for the call please follow the link below:

<https://services.choruscall.com.au/diamondpass/vtivation-628655-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call. Alternatively you can dial in using the details below at the scheduled call start time.

Conference ID: 628 655

Participant Dial In Numbers

Australia Toll Free: 1 800 558 698

Australia Local: 02 9007 3187

New Zealand Toll Free: 0800 453 055

Hong Kong: 800 966 806

Singapore: 800 101 2785

United Kingdom: 0800 051 8245

United States: (855) 881 1339

United Kingdom: 0800 051 8245

US Local (New York): (914) 202 3258

US Local (Los Angeles): (909) 235 4020

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivation.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state

or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR21 r1

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Visioneering Technologies, Inc.

ABN

616 156 248

Quarter ended ("current quarter")

September 30, 2017

Consolidated statement of cash flows	Current quarter US\$'000	Year to date (9months) US\$'000
1. Cash flows from operating activities		
1.1 Receipts from customers	177	409
1.2 Payments for		
(a) research and development	(178)	(366)
(b) product manufacturing and operating costs	(1,019)	(3,559)
(c) advertising and marketing	(367)	(621)
(d) leased assets	-	-
(e) staff costs	(1,619)	(3,452)
(f) administration and corporate costs	(508)	(1,554)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	44	44
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(3,470)	(9,099)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(87)	(121)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter US\$'000	Year to date (9months) US\$'000
(d) intellectual property	(6)	(16)
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(93)	(137)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	25,951
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(2,557)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	23,394

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	23,395	5,674
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(3,470)	(9,099)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(93)	(137)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	23,394

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (9months) US\$'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	19,832	19,832

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US\$'000	Previous quarter US\$'000
5.1	Bank balances	250	235
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (#)	19,582	23,160
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	19,832	23,395

U.S. Treasury bills, notes, and other high-quality, short term securities that are issued or guaranteed by the U.S. government or by U.S. government agencies.

6.	Payments to directors of the entity and their associates	Current quarter US\$'000
6.1	Aggregate amount of payments to these parties included in item 1.2	50
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7.	Payments to related entities of the entity and their associates	Current quarter US\$'000
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available

Add notes as necessary for an understanding of the position

Total facility amount at quarter end US\$'000	Amount drawn at quarter end US\$'000
-	-
-	-
-	-

8.1 Loan facilities

8.2 Credit standby arrangements

8.3 Other (please specify)

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--	--

9. Estimated cash outflows for next quarter

US\$'000

9.1	Research and development	312
9.2	Product manufacturing and operating costs	994
9.3	Advertising and marketing	382
9.4	Leased assets	-
9.5	Staff costs	2,254
9.6	Administration and corporate costs	350
9.7	Other (provide details if material)	-
9.8	Total estimated cash outflows	4,292

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)


Acquisitions

Disposals

10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  Date: 18 October 2017

(Director/Company secretary)

Print name: Stephen Snowdy

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.